Prices controls have always disrupted the marketplace and created shortages or excesses.
The Case for 340B Reform Is Made on Capitol Hill
At a Capitol Hill briefing on the urgent need for reforms to the 340B Drug Pricing Program, the case was made for prompt action to fix the program. The event took place at the Senate Visitors Center on September 23, 2024, and was hosted by the Council for Citizens Against Government Waste (CCAGW). The panel […]
USPTO-FDA Study Debunks Critics and Demonstrates the Importance of Protecting IP
USPTO-FDA study reinforces the need to protect pharmaceutical intellectual property rights for the future of new drug development.
The IRA Has Undermined Medicare Part D
The Inflation Reduction Act creates instability in the Medicare Part D Program.
Not-So-Happy Birthday to the Inflation Reduction Act
The Inflation Reduction Act will ultimately raise drug costs and reduce future cures.
New Study Shows PBMs Lower Drug Prices
A new report challenges assertions made during the committee’s recent hearing on the role of pharmacy benefit managers.
The FTC Wrongly Blames PBMs for High Drug Prices
The FTC fails to acknowledge the benefits of pharmacy benefit managers and wrong blames them for high drug prices.
CCAGW Urges House of Representatives to Oppose H.R. 8371
Title V of H.R. 8371 would slow deployments and improvements to the VA electronic health record management system.
FDA Has Once Again Delayed Its Menthol Ban
A federal flavor ban is clearly unpopular and would create black markets.
Southern States Advance Harmful Tobacco Legislation
Pre-market application requirements for THR products injure public health and finances.